Tern invests £78,000 in Device Authority through 8% convertible loan notes

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that it is investing US$104,111 (approximately £78,000) in new unsecured convertible loan notes to be issued by Device Authority Limited.  The investment in the Device Authority CLNs will be funded from the proceeds of the Company’s recent Open Offer.

The Device Authority CLNs carry an interest rate of 8 per cent. per annum and the Device Authority CLNs’ principal amount and accrued interest are convertible on either a change of control of Device Authority, or a fundraising of at least US$5 million undertaken by Device Authority, or, if neither has occurred on 30 June 2027.  On a change of control, the Device Authority CLNs are convertible at a three times multiple to their face value and the value of accrued interest.  On a Qualifying Fundraise the Device Authority CLNs are convertible at a 25 per cent discount to the Qualifying Fundraise price.  If neither a change of control nor a Qualifying Fundraise has taken place, the Device Authority CLNs will mature on 30 June 2027.

As at 30 June 2026, the date of Tern’s last published book valuation, Tern’s holding in Device Authority had a total unaudited book value of £4.1 million. Following the issue of the Device Authority CLN, Tern’s equity holding in Device Authority will be unchanged and Tern will continue to hold approximately 26.6% of Device Authority’s equity (before any dilution on exercise of share options), although now with a Device Authority CLN holding of approximately £0.29 million.

As part of the same overall funding round, Device Authority is in the process of raising up to US$0.9 million of funding from existing investors through the issue of Device Authority CLNs on the same terms.

Further information on Device Authority

Device Authority is a global leader in Identity and Access Management (“IAM”) for the IoT; focused on the automotive, medical device and industrial sectors. Device Authority’s KeyScaler™ platform provides zero touch provisioning and complete automated lifecycle management for securing IoT devices and data at scale, with frictionless deployment across device provisioning, authentication, credential management, policy based end-to-end data security/encryption and secure OTA (over the air) and HSM (hardware security module) updates.

Based on Device Authority’s latest statutory accounts for the year ended 31 December 2025, as at that date it had net assets of approximately £11,609,000 and incurred a loss for the year of approximately £1,750,000. Given the historic and statutory nature of these figures, Tern does not consider this to be representative of the current business, trading performance and prospects of Device Authority.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual interest. The investment will increase Tern’s loan note holding to approximately £290,000, alongside its existing 26.6% equity stake.

Device Authority highlights security risks as AI begins controlling physical machines

Device Authority examines the security risks of AI-controlled machinery and the role of device identity, authentication and access controls in protecting physical equipment.

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies.

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

Search